14
Participants
Start Date
July 8, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
April 4, 2025
Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
All patients in the study will have organoid creation and organoid drug sensitivity screening attempted on their fresh tumor tissue from surgical resection. All patients will also have blood taken pre-operatively and at multiple post-operative time points to monitor circulating tumor DNA.
University of Illinois at Chicago, Chicago
University of Washington, Seattle
Collaborators (1)
Natera, Inc.
INDUSTRY
SEngine Precision Medicine, Inc.
UNKNOWN
University of Washington
OTHER